Cell Lysis And Disruption Global Market Report 2025

The cell lysis and disruption market size has grown strongly in recent years. It will grow from $4.91 billion in 2024 to $5.34 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. Growth during the historic period can be attributed to the expansion of biopharmaceutical research and development efforts, the growing trend of outsourcing bioprocessing to contract development and manufacturing organizations (CDMOs), the demand for efficient upstream processing in biomanufacturing, increased investments in gene therapy research, and a rise in clinical trials utilizing viral vectors.

The cell lysis and disruption market size is expected to see strong growth in the next few years. It will grow to $7.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. Growth in the forecast period can be attributed to the advancement of genomics, transcriptomics, and proteomics, the increasing applications of single-cell analysis, expanded funding for academic and research institutions, the global rise in infectious disease prevalence, and the growing incidence of cancer and other chronic illnesses. Key trends anticipated during this period include the development of advanced cell lysis techniques, automation in sample preparation workflows, integration of lysis technologies into lab-on-chip systems, the emergence of high-throughput cell lysis platforms, and improved buffer formulations designed for selective lysis.

The growing emphasis on personalized medicine is expected to drive the expansion of the cell lysis and disruption market in the coming years. Personalized medicine refers to a healthcare approach that customizes treatment and care based on an individual’s unique characteristics, such as genetic makeup and lifestyle. The demand for personalized medicine is increasing due to advancements in genomic technologies, which facilitate the precise identification of disease-causing genetic variations, thereby enabling more targeted and effective therapies. The rising need for personalized medicine supports the use of cell lysis and disruption, as these techniques are crucial for isolating Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA), and proteins from patient samples, allowing for the molecular analysis necessary to develop customized treatments. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (USFDA) approved 16 new personalized therapies for rare disease patients in 2023, a notable increase from 6 approvals in 2022. Thus, the growing focus on personalized medicine is expected to fuel the growth of the cell lysis and disruption market.

Leading companies in the cell lysis and disruption market are prioritizing the development of advanced technologies, such as single-cell microfluidic platforms, to improve the efficiency and capabilities of single-cell analysis in microbial genomics. Single-cell microfluidic platforms are compact devices that enable the precise isolation, handling, and analysis of individual cells by manipulating minute fluid volumes within microchannels. This technology supports high-throughput and automated single-cell research. For example, in January 2024, Atrandi Biosciences Inc., a biotechnology company based in Lithuania, introduced the Flux platform along with the Single-Microbe DNA Barcoding Kit. These innovations incorporate semi-permeable capsule (SPC) technology, which facilitates the efficient isolation and lysis of individual microbial cells while preserving the integrity of downstream reactions. The platform is designed to deliver high-throughput performance, enabling accurate microbial genome quantification and DNA sequencing. Such advancements are vital for progressing microbial genomics and single-cell research by streamlining workflows and making high-resolution analysis more accessible and effective across scientific disciplines.

In July 2023, QIAGEN N.V., a Netherlands-based company specializing in reagents and kits for cell lysis, entered into a partnership with Niba Labs to improve the precision, efficiency, and standardization of molecular diagnostics and drug development processes. This collaboration aims to leverage their combined expertise in digital polymerase chain reaction (PCR) assay development and sample testing to deliver customized solutions for biopharmaceutical companies. These solutions are designed to enhance nucleic acid quantification, increase the accuracy and reproducibility of viral vector titration, and address the growing demand for high-sensitivity analysis in cell and gene therapy. Niba Labs is a Slovenia-based biotechnology firm focused on analytics for cell and gene therapy applications.

Major players in the cell lysis and disruption market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company (BD), Agilent Technologies Inc., IDEX Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Eppendorf AG, Miltenyi Biotec GmbH, Takara Bio Inc., Promega Corporation, New England Biolabs Inc., Cell Signaling Technology Inc., Covaris LLC, Microfluidics International Corp., Parr Instrument Company, Pion Inc., Analytik Ltd., Claremont BioSolutions LLC, Qsonica LLC.

North America was the largest region in the cell lysis and disruption market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cell lysis and disruption report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell lysis and disruption market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell lysis and disruption are processes that compromise or break the integrity of a cell’s membrane, leading to the release of its internal contents. Cell lysis specifically involves breaking the cell membrane or wall through chemical, enzymatic, or biological methods. On the other hand, cell disruption encompasses a broader range of techniques, including mechanical methods such as sonication, bead milling, or homogenization, as well as non-mechanical strategies, which are particularly useful for more resilient cells like bacteria or yeast. Although cell lysis falls under the umbrella of cell disruption, both processes are aimed at accessing intracellular materials for use in research or biotechnology.

The primary products in cell lysis and disruption include reagents and consumables, as well as instruments. Reagents and consumables consist of chemical agents and single-use items - such as buffers, enzymes, detergents, tubes, and pipette tips - used to break open cells and extract their contents for downstream analysis. These processes are applied to a variety of cell types, including bacterial cells, mammalian cells, plant cells, and yeast, fungi, or algae. Applications include cell organelle isolation, protein extraction, downstream processing, and nucleic acid isolation. The end users span pharmaceutical and biotechnology companies, academic and research institutions, and others.

The cell lysis and disruption market research report is one of a series of new reports that provides cell lysis and disruption market statistics, including cell lysis and disruption industry global market size, regional shares, competitors with a cell lysis and disruption market share, detailed cell lysis and disruption market segments, market trends and opportunities, and any further data you may need to thrive in the cell lysis and disruption industry. This cell lysis and disruption market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell lysis and disruption market consists of revenues earned by entities by providing services such as contract cell lysis services, customized sample preparation services, cell disruption protocol development, analytical testing and validation services related to lysates. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell lysis and disruption market also includes sales of bead-based lysis systems, microfluidizer-based cell disruption systems, and pressure-based cell disruptors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.